



COLLEGE of AMERICAN
PATHOLOGISTS

Surveys and Anatomic Pathology Education Programs

Performance Improvement Program in Surgical Pathology

PIP/PIPW-A 2020

Participant Summary

This document is available online in e-LAB Solutions Suite.

© 2020 College of American Pathologists. The CAP does not permit reproduction of any substantial portion of the material in this Report without its written authorization. The CAP hereby authorizes participants in the program to use the material in this Report solely for educational purposes within their own institutions. The CAP prohibits use of the material in the Report — and any unauthorized use of the CAP's name or logo — in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services. Data from this program do not necessarily indicate the superiority or inferiority of instruments, reagents, or other materials used by participating laboratories. Use of these data to suggest such superiority or inferiority may be deceptive and misleading. The CAP will take all steps open to it under the law to prevent unauthorized reproduction of substantial portions of the material in this Report, deceptive use of any such material, and any unauthorized use of the CAP's name or logo in connection with promotional efforts by marketers of laboratory equipment, reagents, materials, or services.

**2020 PIP/PIPW-A
PARTICIPANT SUMMARY**

Program Update

This report summarizes the diagnostic responses for set A of the 2020 Performance Improvement Program in Surgical Pathology (PIP & PIPW).

A tabulation of the responses to the supplementary questions is not included since these are intended for educational purposes only.

SURGICAL PATHOLOGY COMMITTEE

Aaron Auerbach, MD FCAP, Chair

Oyedele A. Adeyi, MBBS FCAP	Nilsa C. Ramirez, MD, FCAP
Vijayalakshmi Ananthanarayanan, MD, MBBS FCAP	Kirtee Raparia, MD, FCAP
Phyu Aung, PhD FCAP	Anwar Sultana Sabiha Raza, MD FCAP
Deborah Ann Belchis, MD FCAP	Vijaya B. Reddy, MD, MBA FCAP
Lynden Praul Bowden III, MD FCAP	Safia N. Salaria, MD FCAP
Miriam Conces, MD FCAP	Robert A. Schwartz, MD FCAP
Rajan Dewar, MD, PhD FCAP	Rochelle A Simon, MD, FCAP
Leslie Dodd, MD FCAP	Sabrina C. Sopha, MD FCAP
Raul Gonzalez, MD FCAP	Nichole L. Steidler, MD FCAP
Christina Isacson, MD FCAP	Justin M. Wells, MD FCAP
Xiaoyin Jiang, MD FCAP	Danielle E. Westfall, MD FCAP
Archi Patel, MD	

Case # 2020-01

Diagnosis

(2951) High-grade (conventional) osteosarcoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2951	High-grade (conventional) osteosarcoma	5875	97.6	213	66.8
2757	Low-grade central osteosarcoma	86	1.4	57	17.9
2727	Parosteal osteosarcoma	40	0.7	30	9.4
2919	Periosteal osteosarcoma	16	0.3	19	6.0

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2683	48.4
002		1186	21.4
003	Satisfactory	1390	25.1
004		214	3.9
005	Unsatisfactory	65	1.2

Case # 2020-02

Diagnosis

(1700) Myxoid liposarcoma (MLS)

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1700	Myxoid liposarcoma (MLS)	5965	99.0	276	90.2
1511	Pleomorphic liposarcoma (PLS)	35	0.6	9	2.9
1753	Spindle cell lipoma	7	0.1	6	2.0
2256	Well-differentiated liposarcoma (WD-LPS)	17	0.3	15	4.9

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2817	51.4
002		1128	20.6
003	Satisfactory	1322	24.1
004		176	3.2
005	Unsatisfactory	36	0.7

Case # 2020-03

Diagnosis

(5652) High-grade serous ovarian carcinoma with SET features

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5650	Conventional high-grade serous ovarian carcinoma	103	1.7	45	15.0
5651	Endometrioid adenocarcinoma of the ovary	30	0.5	26	8.6
5652	High-grade serous ovarian carcinoma with SET features	5781	95.9	195	64.8
5653	Low-grade serous ovarian carcinoma	11	0.2	3	1.0
1743	Malignant Brenner tumor	101	1.7	32	10.6
5654	Metastatic urothelial carcinoma of the bladder	2	<0.1	0	0.0

Technical Quality of Slide

Ratin	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2917	53.5
002		1136	20.8
003	Satisfactory	1270	23.3
004		107	2.0
005	Unsatisfactory	22	0.4

Case # 2020-04

Diagnosis

(5655) Metaplastic breast carcinoma with mesenchymal differentiation

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1189	Malignant phyllodes tumor	6	0.1	1	0.3
5655	Metaplastic breast carcinoma with mesenchymal differentiation	5937	98.5	221	74.9
5659	Metastatic carcinosarcoma	14	0.2	12	4.1
5656	Primary chondroid osteosarcoma	6	0.1	6	2.0
5657	Radiation-induced osteosarcoma	63	1.1	55	18.6

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2867	52.6
002		1141	21.0
003	Satisfactory	1284	23.6
004		130	2.4
005	Unsatisfactory	20	0.4

Case # 2020-05

Diagnosis

(2339) Follicular lymphoma, grade 3A

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2453	Burkitt lymphoma	3	0.1	6	2.0
1772	Chronic lymphocytic leukemia/small lymphocytic lymphoma	8	0.1	3	1.0
2454	Diffuse large B-cell lymphoma	106	1.8	70	23.9
1686	Follicular lymphoma, grade 1-2	140	2.3	44	15.0
2339	Follicular lymphoma, grade 3A	5739	95.3	149	50.9
5638	High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements	28	0.5	21	7.2

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2756	51.0
002		1168	21.6
003	Satisfactory	1327	24.5
004		132	2.4
005	Unsatisfactory	25	0.5

Case # 2020-06

Diagnosis

(2414) Acinar cell carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
2414	Aspiration pneumonia	5927	98.4	207	71.6
2485	Hepatocellular carcinoma	3	0.1	3	1.0
5658	Mixed acinar-neuroendocrine carcinoma	57	0.9	37	12.8
1305	Pancreatic ductal adenocarcinoma	10	0.2	5	1.7
2298	Pancreatic neuroendocrine tumor	17	0.3	10	3.5
2418	Pancreatoblastoma	6	0.1	19	6.6
2300	Solid-pseudopapillary neoplasm	2	<0.1	8	2.8

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2885	53.4
002		1090	20.2
003	Satisfactory	1278	23.6
004		132	2.4
005	Unsatisfactory	23	0.4

Case # 2020-07

Diagnosis

(2889) Salivary duct carcinoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1547	Acinic cell carcinoma	49	0.8	11	3.8
1721	Adenoid cystic carcinoma	16	0.3	9	3.1
1881	Mucoepidermoid carcinoma	10	0.2	7	2.4
2889	Salivary duct carcinoma	5899	97.8	232	80.8
5660	Secretory carcinoma	52	0.9	28	9.8

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2884	53.1
002		1093	20.1
003	Satisfactory	1314	24.2
004		118	2.2
005	Unsatisfactory	21	0.4

Case # 2020-08

Diagnosis

(1736) Well-differentiated neuroendocrine tumor

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1424	Epithelioid gastrointestinal stromal tumor	11	0.2	1	0.4
2251	Gangliocytic paraganglioma	31	0.5	4	1.4
1674	Metastatic melanoma	6	0.1	0	0.0
1539	Poorly differentiated neuroendocrine carcinoma	40	0.7	15	5.3
1736	Well-differentiated neuroendocrine tumor	5797	98.5	264	93.0

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2559	47.1
002		938	17.3
003	Satisfactory	1170	21.5
004		190	3.5
005	Unsatisfactory	577	10.6

Case # 2020-09

Diagnosis

(2716) Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
5661	Colonic adenocarcinoma	2	<0.1	2	0.7
2716	Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)	5989	99.5	257	90.2
1934	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)	20	0.3	24	8.4
1674	Metastatic melanoma	3	0.1	0	0.0
1539	Poorly differentiated neuroendocrine carcinoma	2	<0.1	2	0.7

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2912	54.0
002		1093	20.3
003	Satisfactory	1265	23.4
004		110	2.0
005	Unsatisfactory	16	0.3

Case # 2020-10

Diagnosis

(1990) Splenic marginal zone lymphoma

Code	Diagnosis	PIP Participants		PIPW Participants	
		No.	%	No.	%
1772	Chronic lymphocytic leukemia/small lymphocytic lymphoma	8	0.1	5	1.8
1800	Follicular lymphoma	5	0.1	7	2.5
1630	Hairy cell leukemia	38	0.6	29	10.2
2334	Mantle cell lymphoma rearrangements	12	0.2	3	1.1
5628	Splenic diffuse red pulp B-cell lymphoma	180	3.0	38	13.4
1990	Splenic marginal zone lymphoma	5776	96.0	202	71.1

Technical Quality of Slide

Rating	Glass Slide Evaluation	PIP Participants	
		No.	%
001	Excellent	2819	52.0
002		1154	21.3
003	Satisfactory	1326	24.5
004		95	1.8
005	Unsatisfactory	20	0.4

This concludes the report.



COLLEGE of AMERICAN
PATHOLOGISTS

325 Waukegan Road
Northfield, IL 60093-2750
800-323-4040
847-832-7000 (Country code: 001)